A 20-year RRM uptake of 48% among BRCA1/BRCA2 PV carriers and up to 9% among non-CSG carriers with 30% or higher lifetime BC risk was reported by the Manchester high-risk prevention clinic.14 However, previously, RRM access for non-CSG carriers has been rare, patchy, and lacked clinical consensus. This evidence concerns the gene BRCA2 and breast cancer.